US Genotyping Market Summary

As per Market Research Future analysis, the US genotyping market Size was estimated at 677.59 USD Million in 2024. The US genotyping market is projected to grow from 737.83 USD Million in 2025 to 1728.56 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.8% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The US genotyping market is experiencing robust growth driven by technological advancements and increasing demand for personalized medicine.

Technological advancements are enhancing the accuracy and efficiency of genotyping processes.
The demand for personalized medicine is driving significant growth in the genotyping market, particularly in oncology and rare diseases.
Regulatory support and funding are fostering innovation and expansion within the genotyping sector.
Rising prevalence of genetic disorders and increased investment in genomic research are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size	677.59 (USD Million)
2035 Market Size	1728.56 (USD Million)
CAGR (2025 - 2035)	8.89%

Major Players

Illumina (US), Thermo Fisher Scientific (US), Qiagen (DE), Roche (CH), Agilent Technologies (US), Bio-Rad Laboratories (US), PerkinElmer (US), BGI Genomics (CN)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

US Genotyping Market Trends

The genotyping market is currently experiencing notable growth, driven by advancements in technology and increasing demand for personalized medicine. The integration of high-throughput sequencing and microarray technologies has revolutionized the way genetic information is analyzed, allowing for more efficient and accurate genotyping processes. Furthermore, the rising prevalence of genetic disorders and the growing emphasis on preventive healthcare are propelling the need for genotyping services. As healthcare providers and researchers seek to understand genetic variations, the market is likely to expand, fostering innovation and collaboration among stakeholders. In addition, regulatory support and funding initiatives from government bodies are enhancing the landscape of the genotyping market. These efforts aim to promote research and development, thereby facilitating the introduction of novel genotyping solutions. The increasing awareness of genetic testing among consumers is also contributing to market dynamics, as individuals seek insights into their genetic predispositions. Overall, the future of the genotyping market appears promising, with potential for further advancements and applications in various fields, including pharmacogenomics and agriculture.

Technological Advancements

Recent innovations in sequencing technologies are transforming the genotyping market. High-throughput sequencing methods are enabling faster and more cost-effective analysis of genetic material, which is essential for both clinical and research applications. This trend suggests a shift towards more accessible genotyping solutions, potentially increasing the adoption rate among healthcare providers.

Personalized Medicine Demand

The growing focus on personalized medicine is significantly influencing the genotyping market. As healthcare shifts towards tailored treatments based on individual genetic profiles, the demand for genotyping services is likely to rise. This trend indicates a broader acceptance of genetic testing as a standard practice in medical care.

Regulatory Support and Funding

Government initiatives aimed at supporting genetic research are playing a crucial role in the evolution of the genotyping market. Increased funding and favorable regulations are encouraging innovation and development of new genotyping technologies. This trend highlights the importance of public policy in shaping the future landscape of genetic testing.

US Genotyping Market Drivers

Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders in the US is a pivotal driver for the genotyping market. As awareness of genetic conditions grows, healthcare providers are more inclined to utilize genotyping technologies for diagnosis and treatment. Reports indicate that approximately 1 in 33 infants is born with a genetic disorder, which underscores the necessity for advanced genetic testing. This trend is likely to propel the demand for genotyping services, as early detection can lead to better health outcomes. Furthermore, the genotyping market is expected to witness a compound annual growth rate (CAGR) of around 10% over the next five years, driven by the need for effective genetic screening and personalized treatment options.

Growing Demand for Companion Diagnostics

The rise of companion diagnostics is reshaping the landscape of the genotyping market. These tests, which are designed to determine the suitability of specific therapies for individual patients, are increasingly being integrated into treatment protocols. The market for companion diagnostics is projected to reach $6 billion by 2026, reflecting a growing recognition of the importance of personalized medicine. As pharmaceutical companies collaborate with diagnostic firms, the demand for genotyping services is expected to escalate. This trend not only enhances patient outcomes but also drives the need for more sophisticated genotyping technologies, thereby propelling market growth.

Increased Investment in Genomic Research

Investment in genomic research is a significant catalyst for the growth of the genotyping market. Federal funding and private sector investments have surged, with the National Institutes of Health (NIH) allocating substantial resources to genomics research. This financial support fosters innovation in genotyping technologies, enhancing their accuracy and efficiency. The US government has committed over $1 billion annually to genomic research initiatives, which is likely to stimulate advancements in genotyping methodologies. As research progresses, the applications of genotyping are expanding, leading to a broader acceptance in clinical settings and a projected market growth of 12% annually.

Expansion of Direct-to-Consumer Genetic Testing

The expansion of direct-to-consumer (DTC) genetic testing is a notable driver for the genotyping market. Consumers are increasingly seeking insights into their genetic makeup for health, ancestry, and lifestyle purposes. The DTC genetic testing market is anticipated to exceed $1 billion by 2025, indicating a robust interest among the public. This trend encourages companies to innovate and offer more comprehensive genotyping services. As consumers become more informed about their genetic risks, the demand for professional genetic counseling and testing services is likely to rise, further stimulating the genotyping market.

Advancements in Bioinformatics and Data Analysis

Advancements in bioinformatics and data analysis are crucial for the evolution of the genotyping market. The ability to analyze vast amounts of genetic data efficiently is transforming how genotyping results are interpreted and utilized. With the integration of artificial intelligence and machine learning, the accuracy and speed of genetic data analysis are improving significantly. This technological evolution is expected to enhance the overall efficiency of genotyping processes, making them more accessible and cost-effective. As a result, the market is projected to grow at a rate of 11% annually, driven by the increasing reliance on data-driven insights in genetic research and clinical applications.

Market Segment Insights

By Technology: Sequencing (Largest) vs. Capillary Electrophoresis (Fastest-Growing)

The US genotyping market is predominantly driven by the Sequencing segment, which commands the largest share due to its extensive applications in research and clinical diagnostics. Capillary Electrophoresis follows closely, catering to specific niche applications but is rapidly gaining traction and expanding its market share, fueled by innovative technological advancements and an increasing focus on genetic analysis. Growth in the US genotyping market is being markedly influenced by technological advancements and the rising prevalence of genetic disorders, propelling the demand for effective genotyping methods. Sequencing continues to innovate, with next-gen technologies streamlining processes and efficiency. Meanwhile, Capillary Electrophoresis is recognized as the fastest-growing segment, driven by its adaptability and precision in analyzing genetic materials, appealing to both researchers and healthcare providers.

Technology: Sequencing (Dominant) vs. Capillary Electrophoresis (Emerging)

Sequencing is the dominant technology within the US genotyping market, characterized by its high throughput capabilities and versatility in various applications such as whole-genome sequencing and targeted sequencing. It stands out for its ability to generate vast quantities of data, fundamentally transforming genetic research and personalized medicine. On the other hand, Capillary Electrophoresis is an emerging technology, valued for its accuracy and efficiency in separating nucleic acids and proteins. Its growing adoption in forensic analysis and clinical diagnostics highlights its potential, as it becomes indispensable in the evolving landscape of genetic analysis, benefiting from advancements that improve speed and reliability.

By Product: Reagents and Kits (Largest) vs. Instruments (Fastest-Growing)

In the US genotyping market, the distribution of market share among the product segments reveals that reagents and kits dominate significantly. This segment is favored for its critical role in genetic analysis, providing essential materials for accurate and efficient genotyping processes. Instruments, while currently holding a smaller share, are quickly gaining traction due to technological advancements and increased investments in automation and precision within laboratories. Growth trends in this market are becoming increasingly favorable for instruments owing to innovations such as real-time PCR and next-generation sequencing technologies. These advancements not only enhance the speed and accuracy of genetic testing but also broaden the application range of these instruments in clinical diagnostics and research environments. Furthermore, the rise in personalized medicine initiatives is driving demand for diverse reagents and kits, solidifying their market position while fostering competition across both segments.

Reagents and Kits (Dominant) vs. Instruments (Emerging)

Reagents and kits serve as the backbone of the US genotyping market, characterized by their extensive utilization across research and clinical settings. They are integral for various applications, including disease diagnostics and genetic research. The focus on quality and reproducibility sets a high benchmark for manufacturers in this segment. Conversely, instruments are emerging rapidly as essential tools in the market, supported by continuous technological innovations. As laboratories embrace automation and require enhanced throughput, instruments that offer improved performance and reliability are poised for significant growth. Both segments play pivotal roles in shaping the future landscape of the industry, with reagents and kits maintaining dominance while instruments surge ahead, driven by new capabilities.

By Application: Drug Discovery and Development (Largest) vs. Academic Research (Fastest-Growing)

In the US genotyping market, the distribution of market share among the application segments indicates that Drug Discovery and Development holds a significant portion of the market, reinforcing its importance in biopharmaceutical advancements. This segment is pivotal due to the increasing importance of personalized medicine and the growing demand for innovative therapeutic solutions, enabling researchers to develop targeted treatments based on genetic information. On the other hand, Academic Research is emerging as the fastest-growing segment, driven by the surging investment in academic institutions and research facilities. This growth is supported by the expansive initiatives for genetic research and an increasing number of collaborations between academia and industry, which are collectively unlocking new avenues for discovery and technological innovation in genomics.

Drug Discovery: Dominant vs. Academic Research: Emerging

The Drug Discovery and Development segment remains dominant in the US genotyping market, characterized by its extensive utilization of genomic data to inform drug development processes and enhance therapeutic efficacy. This segment benefits from robust funding, knowledgeable professionals, and advanced technologies, which streamlines the transition from research to market-ready products. Conversely, the Academic Research segment is emerging rapidly, marked by a surge in innovative studies and collaborative projects that expand the understanding of genetics. This segment thrives on grant funding and partnerships, enabling it to explore novel methodologies and applications that may significantly impact both medical and scientific communities.

By End User: Hospitals (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US genotyping market, the distribution of market share among key end users highlights hospitals as the dominant player, leveraging their extensive networks and resources to implement advanced genotyping technologies. Diagnostic centers follow closely behind, experiencing a rapid ascent due to their focused services in genetic testing, which is expanding in demand as patients increasingly seek personalized medicine solutions. The growth trends within this segment point towards a significant increase in the adoption of genotyping technologies, particularly driven by advancements in genomic research and the rising incidence of genetic disorders. Hospitals are capitalizing on their integrated healthcare systems to streamline genotyping processes, while diagnostic centers are emerging as critical players, offering specialized services that cater to an evolving healthcare landscape emphasizing precision and efficiency.

Hospitals (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals exhibit a dominant position in the US genotyping market, benefiting from their established infrastructures and broad access to patient populations. Their ability to integrate genotyping tests into routine clinical practices enhances their service offerings, making them indispensable in patient care. On the other hand, diagnostic centers are becoming significant contributors to the market by providing specialized and rapid testing services tailored to genetic conditions. They address niche demands with flexibility and efficiency, attracting a growing number of consumers seeking timely genetic assessments. As both segments evolve, collaboration between hospitals and diagnostic centers is expected to enhance service delivery and innovation in the realm of genetic testing.

Get more detailed insights about US Genotyping Market

Request Free Sample

Key Players and Competitive Insights

The genotyping market exhibits a dynamic competitive landscape characterized by rapid technological advancements and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Agilent Technologies (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on expanding its product offerings and enhancing sequencing technologies, while Thermo Fisher Scientific (US) emphasizes its comprehensive portfolio and integration of digital solutions to streamline workflows. Agilent Technologies (US) is also investing in R&D to develop cutting-edge genotyping solutions, thereby contributing to a competitive environment that prioritizes technological superiority and customer-centric approaches.The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce lead times and enhance responsiveness to market demands. This strategy not only improves operational efficiency but also allows for better alignment with regional regulatory requirements. The collective influence of these key players shapes a competitive landscape where innovation and operational excellence are paramount.
In October Illumina (US) announced a strategic partnership with a leading biotechnology firm to co-develop next-generation sequencing technologies aimed at enhancing genomic research capabilities. This collaboration is expected to accelerate the development of innovative solutions that could significantly improve the accuracy and efficiency of genotyping processes. Such partnerships are indicative of a broader trend towards collaborative innovation in the market.
In September Thermo Fisher Scientific (US) launched a new line of genotyping assays designed to facilitate high-throughput screening in clinical settings. This product introduction not only strengthens its market position but also reflects the company's commitment to addressing the growing demand for rapid and reliable genotyping solutions. The launch is likely to enhance customer engagement and expand its footprint in the clinical diagnostics sector.
In August Agilent Technologies (US) expanded its global reach by establishing a new manufacturing facility in Asia, aimed at increasing production capacity for its genotyping products. This strategic move is anticipated to enhance supply chain efficiency and reduce costs, thereby positioning Agilent favorably against competitors. The establishment of this facility underscores the importance of geographical diversification in meeting global market demands.
As of November the competitive trends in the genotyping market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into workflows. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative efforts in driving innovation. The competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements, reliability in supply chains, and the ability to deliver innovative solutions that meet the specific needs of diverse customer segments.

Key Companies in the US Genotyping Market include

Industry Developments

In recent months, the US Genotyping Market has witnessed significant developments, particularly with companies like Illumina, Thermo Fisher Scientific, and Qiagen. Notably, Illumina has launched new products enhancing genome sequencing accuracy, further solidifying its market position. In March 2023, Thermo Fisher Scientific announced its acquisition of a smaller biotech firm to expand its genotyping capabilities, augmenting its product offerings in the precision medicine space. This move is part of a broader trend where companies like Fulgent Genetics and Helix are increasing their Research and Development investments, which have been reported to enhance product pipelines and overall market competition.

Growth in the market valuation of these companies reflects the rising demand for genotyping in areas such as personalized medicine and clinical diagnostics. Furthermore, the National Institutes of Health reported that federal funding for genomic research has substantially increased over the past two years, facilitating advancements in genotyping technology. Also, key partnerships between companies like Agilent Technologies and New England Biolabs have emerged to foster innovation in high-throughput genotyping solutions, indicating a collaborative approach to market challenges. All these developments highlight a vibrant and rapidly evolving landscape in the US Genotyping Market.

Future Outlook

US Genotyping Market Future Outlook

The Genotyping Market is projected to grow at an 8.89% CAGR from 2025 to 2035, driven by advancements in technology, increasing demand for personalized medicine, and rising research funding.

New opportunities lie in:

Development of high-throughput genotyping platforms for large-scale studies. Expansion of direct-to-consumer genotyping services targeting health-conscious consumers. Partnerships with biotech firms to enhance genotyping applications in drug development.

By 2035, the genotyping market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

Market Segmentation

US Genotyping Market Product Outlook

Reagents and Kits
Instruments
Services

US Genotyping Market End User Outlook

Hospitals
Diagnostic Centers
Academic Institutes
Research and Development Centers

US Genotyping Market Technology Outlook

Sequencing
Capillary Electrophoresis
Polymerase Chain Reaction (PCR)
Others

US Genotyping Market Application Outlook

Drug Discovery and Development
Academic Research
Research and Development Centers

Report Scope

MARKET SIZE 2024	677.59(USD Million)
MARKET SIZE 2025	737.83(USD Million)
MARKET SIZE 2035	1728.56(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.89% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	Illumina (US), Thermo Fisher Scientific (US), Qiagen (DE), Roche (CH), Agilent Technologies (US), Bio-Rad Laboratories (US), PerkinElmer (US), BGI Genomics (CN)
Segments Covered	Technology, Product, Application, End User
Key Market Opportunities	Advancements in personalized medicine drive demand for innovative genotyping technologies and services.
Key Market Dynamics	Technological advancements drive innovation in genotyping, enhancing precision and efficiency in genetic analysis.
Countries Covered	US

FAQs

What was the overall valuation of the US genotyping market in 2024?

The overall market valuation was $677.59 Million in 2024.

What is the projected market valuation for the US genotyping market by 2035?

The projected valuation for 2035 is $1728.56 Million.

What is the expected CAGR for the US genotyping market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 8.89%.

Which companies are considered key players in the US genotyping market?

Key players include Illumina, Thermo Fisher Scientific, Qiagen, Roche, Agilent Technologies, Bio-Rad Laboratories, PerkinElmer, and BGI Genomics.

What are the main technology segments in the US genotyping market?

Main technology segments include Sequencing, Capillary Electrophoresis, Polymerase Chain Reaction (PCR), and Others.

What was the market size for Sequencing technology in 2024?

The market size for Sequencing technology was between $200.0 Million and $500.0 Million in 2024.

How much revenue did Reagents and Kits generate in the US genotyping market in 2024?

Reagents and Kits generated revenue between $250.0 Million and $650.0 Million in 2024.

What applications are driving growth in the US genotyping market?

Applications driving growth include Drug Discovery and Development, Academic Research, and Research and Development Centers.

Which end users are most prominent in the US genotyping market?

Prominent end users include Hospitals, Diagnostic Centers, Academic Institutes, and Research and Development Centers.

What is the expected growth trend for the US genotyping market in the coming years?

The market is expected to grow steadily, reaching $1728.56 Million by 2035, driven by advancements in technology and increasing applications.

Author

Author

Satyendra Maurya

Research Analyst

An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.

Co-Author

Garvit Vyas

Vice President - Operations

Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.

Get In Touch

Leave a Comment